The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community.
D. A. Patt
Employment or Leadership Position - US Oncology
J. L. Espirito
No relevant relationships to disclose
B. Turnwald
No relevant relationships to disclose
J. R. Hoverman
Employment or Leadership Position - US Oncology
M. A. Neubauer
Employment or Leadership Position - US Oncology
L. T. Busby
No relevant relationships to disclose
B. D. Brooks
Consultant or Advisory Role - Amgen
Honoraria - Eisai
M. A. Kolodziej
Employment or Leadership Position - US Oncology
R. W. Anderson
No relevant relationships to disclose
R. A. Beveridge
Employment or Leadership Position - US Oncology
Honoraria - US Oncology
Research Funding - US Oncology